---
layout: post
title: New Drug Approvals 2012 - Pt. XX - Bosutinib (BosulifÂ®)
date: '2012-09-25T20:59:00.003+01:00'
author: Sam Croset
tags:
- Small Molecule Drugs
- Kinase inhibitor
- 2012 New Drugs
modified_time: '2012-09-26T12:23:36.016+01:00'
thumbnail: http://2.bp.blogspot.com/-F-ODUz5hwAs/UGF00Js7yYI/AAAAAAAABuw/4w1Kq2gkMyc/s72-c/bosulif.png
blogger_id: tag:blogger.com,1999:blog-2546008714740235720.post-3731010566324108325
blogger_orig_url: http://chembl.blogspot.com/2012/09/new-drug-approvals-2012-pt-xx-bosutinib.html
---

<div dir="ltr" style="text-align: left;" trbidi="on">
<div class="separator" style="clear: both; text-align: center;">
<a href="http://2.bp.blogspot.com/-F-ODUz5hwAs/UGF00Js7yYI/AAAAAAAABuw/4w1Kq2gkMyc/s1600/bosulif.png" imageanchor="1" style="margin-left: 1em; margin-right: 1em;"><img border="0" height="92" src="http://2.bp.blogspot.com/-F-ODUz5hwAs/UGF00Js7yYI/AAAAAAAABuw/4w1Kq2gkMyc/s320/bosulif.png" width="320" /></a></div>
<div class="separator" style="clear: both; text-align: center;">
<br /></div>
<div class="separator" style="clear: both; text-align: center;">
</div>
<div class="separator" style="clear: both; text-align: center;">
<a href="https://www.ebi.ac.uk/chembltools/autoiconlarge/1,0,0,1,0,0,0,0,0" imageanchor="1" style="margin-left: 1em; margin-right: 1em;"><img border="0" height="38" src="https://www.ebi.ac.uk/chembltools/autoiconlarge/1,0,0,1,0,0,0,0,0" width="320" /></a></div>
<div class="separator" style="clear: both; text-align: center;">
<br /></div>
<div class="separator" style="clear: both; text-align: center;">
<br /></div>
On September 4th, the FDA&nbsp;approved&nbsp;<a href="http://en.wikipedia.org/wiki/Bosutinib">bosutinib</a> (marketed as Bosulif) for the treatment of patients with previously treated Philadelphia Chromosome-Positive (Ph+)&nbsp;<a href="http://en.wikipedia.org/wiki/Chronic_myelogenous_leukemia">Chronic Myelogenous Leukemia</a> (CML - cancer of the white blood cells).<br />
<br />
Chronic myelogenous leukemia is one of the four most common types of leukemia and is often associated with treatment with imatinib (<a href="https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL941">CHEMBL941</a>) as an initial therapy. However, approximately one-third of patients do not achieve an optimal response with this standard treatment. In such cases, second generation <a href="http://en.wikipedia.org/wiki/Tyrosine_kinase_inhibitor">Tyrosine Kinase Inhibitors</a> are required, but only half of the treated patients show acceptable outcomes. The patients with poor responses to either of these treatments have now the possibility to receive bosutinib (<a href="https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL288441">CHEMBL288441</a>) as alternative therapy.<br />
<br />
As suggested by the '-tinib' prefix (USAN stem), bosutinib is a protein kinase inhibitor (<a href="http://www.whocc.no/atc_ddd_index/?code=L01XE14">ATC:L01XE14</a>). The molecule has a calculated logP of 3.88 and&nbsp;relative molecular weight of 530.4. It is therefore too heavy to satisfy the rule of five (maximum molecular weight of 500). The drug is taken orally with food with a&nbsp;recommendation&nbsp;of 500 mg per day. BOSULIF is available as tablet of 100 and 500 mg.<br />
<div class="separator" style="clear: both; text-align: center;">
<a href="https://www.ebi.ac.uk/chembldb/compound/displayimage_large/62111" imageanchor="1" style="margin-left: 1em; margin-right: 1em;"><img border="0" height="320" src="https://www.ebi.ac.uk/chembldb/compound/displayimage_large/62111" width="320" /></a></div>
<b>Canonical SMILES</b>: COc1cc(Nc2c(cnc3cc(OCCCN4CCN(C)CC4)c(OC)cc23)C#N)c(Cl)cc1Cl<br />
<b>Standard InChI</b>: 1S/C26H29Cl2N5O3/c1-32-6-8-33(9-7-32)5-4-10-36-25-13-21-18(11-24(25)35-3)26(17(15-29)16-30-21)31-22-14-23(34-2)20(28)12-19(22)27/h11-14,16H,4-10H2,1-3H3,(H,30,31)<br />
<b>Standard InChI Key</b>: UBPYILGKFZZVDX-UHFFFAOYSA-N<br />
<br />
<div>
<br /></div>
<div>
As the drug is metabolized by CYP3A4 (<a href="http://www.uniprot.org/uniprot/P08684">UNIPROT:P08684</a>) it could therefore interact with other compounds acting on the enzyme, such as <a href="http://en.wikipedia.org/wiki/P-glycoprotein">P-glycoprotein</a> inhibitors or CYP3 inducers. Proton pump inhibitors can also decrease the drug concentration in the human body.</div>
<br />
Most common adverse reactions (incidence greater than 20%) are diarrhea,&nbsp;nausea, thrombocytopenia, vomiting, abdominal pain, rash, anemia, pyrexia&nbsp;and fatigue.<br />
<br />
The product website is<a href="http://www.bosulif.com/" target="_blank"> www.bosulif.com</a>, full prescribing information is <a href="http://labeling.pfizer.com/ShowLabeling.aspx?id=884" target="_blank">here</a>.</div>
